Investor Relations

EyePoint Pharmaceuticals (Nasdaq: EYPT) is a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The Company's pipeline leverages its proprietary Durasert® technology for sustained intraocular drug delivery including EYP-1901, an investigational sustained delivery intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration. The proven Durasert drug delivery platform has been safely administered to thousands of patients' eyes across four U.S. FDA approved products, including YUTIQ® for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, which is currently marketed by the Company. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.

Recent Releases

Nov 16, 2022
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Nov 07, 2022
EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences
Nov 02, 2022
EyePoint Pharmaceuticals Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate Developments
Oct 26, 2022
EyePoint Pharmaceuticals to Report Third Quarter 2022 Financial Results on November 2, 2022
Oct 17, 2022
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

IR CONTACTS
Stern Investor Relations
p. 212.362.1200
e. eyepoint@sternir.com

MEDIA RELATIONS CONTACT
Amy Phillips
p. 412.327.9499
e. aphillips@greenroompr.com